With Illumina Acquisition on Ice, What is Roche's Next Move in the Sequencing Space? | GenomeWeb

By Monica Heger and Julia Karow

Following Roche's withdrawal of its tender offer for Illumina last week — after courting the firm's shareholders for almost three months — the Swiss drug and diagnostics developer is left to reconsider its options for expanding its portfolio of sequencing technologies.

While it's possible that Roche may still approach Illumina with another offer over the next year, it appears that the company is also looking for new possibilities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.